Target Name: MYO1D
NCBI ID: G4642
Review Report on MYO1D Target / Biomarker Content of Review Report on MYO1D Target / Biomarker
MYO1D
Other Name(s): myosin ID | Unconventional myosin-Id (isoform 1) | KIAA0727 | Myosin-I gamma | Myosin-Id | Myosin ID, transcript variant 1 | Myr4 | myr4 | MYO1D variant 1 | PPP1R108 | protein phosphatase 1, regulatory subunit 108 | myosin-I gamma | Unconventional myosin-Id | MYO1D_HUMAN

MYO1D's Role in Muscle Function and Disease

Myosin ID (MYO1D) is a protein that plays a crucial role in muscle cell function and growth. It is a key regulator of myosin ATPase (also known as myosin light chain) function, which is responsible for generating the energy needed for muscle contraction. MYO1D has also been shown to play a key role in the regulation of muscle size and strength.

Diseases and Disorders

MYO1D dysfunction has been implicated in a number of diseases and disorders, including:

1. Myopathies: Myosin ID is often abnormal in muscles affected by diseases such as dystrophy and myopathies. These conditions are characterized by muscle weakness and/or dysfunction.
2. Myotonic Dystrophy: Myosin ID has been shown to be abnormal in individuals with myotonic dystrophy, a genetic disorder characterized by muscle stiffness and contractions.
3. Cancer: Some studies have suggested that MYO1D may be involved in the regulation of muscle growth and the development of cancer.

The Drug Target Potential

Given the significance of MYO1D in muscle function and disease, it is a promising drug target. Studies have shown that inhibiting MYO1D activity has the potential to treat a number of diseases and disorders.

1. Myopathies: Treatments that target MYO1D have been shown to improve muscle strength and function in individuals with myopathies.
2. Myotonic Dystrophy:MYO1D has been shown to be involved in the development and progression of myotonic dystrophy, and inhibiting its activity has been shown to treat muscle stiffness and contractions in individuals with this condition.
3. Cancer:MYO1D has been shown to be involved in the regulation of muscle growth and the development of cancer, and inhibiting its activity may have the potential to treat cancer.

The Biomarker Potential

MYO1D has also been shown to be a potential biomarker for a number of diseases and disorders. It has been shown to be elevated in the blood of individuals with certain myopathies, and may be a diagnostic marker for these conditions.

MYO1D has also been shown to be elevated in the blood of individuals with certain types of cancer, and may be a potential biomarker for cancer.

Conclusion

MYO1D is a protein that plays a crucial role in muscle cell function and growth, and has been implicated in a number of diseases and disorders. Given its significance, it is a promising drug target and a potential biomarker. Further research is needed to fully understand its role in muscle function and disease.

Protein Name: Myosin ID

Functions: Unconventional myosin that functions as actin-based motor protein with ATPase activity (By similarity). Plays a role in endosomal protein trafficking, and especially in the transfer of cargo proteins from early to recycling endosomes (By similarity). Required for normal planar cell polarity in ciliated tracheal cells, for normal rotational polarity of cilia, and for coordinated, unidirectional ciliary movement in the trachea. Required for normal, polarized cilia organization in brain ependymal epithelial cells (By similarity)

The "MYO1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYO1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MYO1E | MYO1F | MYO1G | MYO1H | MYO3A | MYO3B | MYO3B-AS1 | MYO5A | MYO5B | MYO5C | MYO6 | MYO7A | MYO7B | MYO9A | MYO9B | MYOC | MYOCD | MYOD1 | MYOF | MYOG | MYOM1 | MYOM2 | MYOM3 | MYORG | Myosin | Myosin class II | Myosin light-chain phosphatase | MYOSLID | MYOSLID-AS1 | MYOT | MYOZ1 | MYOZ2 | MYOZ3 | MYPN | MYPOP | MYRF | MYRF-AS1 | MYRFL | MYRIP | MYSM1 | MYT1 | MYT1L | MYT1L-AS1 | MYZAP | MZB1 | MZF1 | MZF1-AS1 | MZT1 | MZT2A | MZT2B | N-acetylglucosamine-1-phosphotransferase | N-CoR deacetylase complex | N-Terminal Acetyltransferase A (NatA) Complex | N-Terminal Acetyltransferase C (NatC) Complex | N-Type Calcium Channel | N4BP1 | N4BP2 | N4BP2L1 | N4BP2L2 | N4BP2L2-IT2 | N4BP3 | N6AMT1 | NAA10 | NAA11 | NAA15 | NAA16 | NAA20 | NAA25 | NAA30 | NAA35 | NAA38 | NAA40 | NAA50 | NAA60 | NAA80 | NAAA | NAALAD2 | NAALADL1 | NAALADL2 | NAALADL2-AS3 | NAB1 | NAB2 | NABP1 | NABP2 | NACA | NACA2 | NACA3P | NACA4P | NACAD | NACC1 | NACC2 | NAD(P)H dehydrogenase, quinone | NAD-Dependent Protein Deacetylase | NADH dehydrogenase (Complex I) | NADK | NADK2 | NADPH Oxidase | NADPH Oxidase Complex | NADSYN1 | NAE1